Compare KRUS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRUS | REPL |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 845.3M | 692.8M |
| IPO Year | 2019 | 2018 |
| Metric | KRUS | REPL |
|---|---|---|
| Price | $56.73 | $2.43 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 9 |
| Target Price | ★ $81.11 | $5.67 |
| AVG Volume (30 Days) | 412.4K | ★ 9.2M |
| Earning Date | 04-07-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.75 | 5.25 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $282,763,000.00 | N/A |
| Revenue This Year | $20.50 | N/A |
| Revenue Next Year | $20.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.88 | N/A |
| 52 Week Low | $42.62 | $1.50 |
| 52 Week High | $95.98 | $13.24 |
| Indicator | KRUS | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 42.16 | 32.40 |
| Support Level | $53.72 | $1.50 |
| Resistance Level | $77.55 | $8.82 |
| Average True Range (ATR) | 5.01 | 0.74 |
| MACD | -0.35 | -0.13 |
| Stochastic Oscillator | 16.00 | 12.88 |
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.